Janssen Biotech and Tesaro entered a worldwide collaboration and exclusive license agreement for the investigational compound niraparib in prostate cancer. The product is an orally administered poly polymerase (PARP) inhibitor, currently in late-stage development for patients with metastatic breast cancer and ovarian cancer. Janssen will have global rights and be responsible for all development and commercialization activities, except in Japan. Tesaro will maintain global development, manufacturing and commercial rights for all other indications. Separate to the exclusive license and collaboration arrangement, Johnson & Johnson Innovation – JJDC, will also make an equity investment in Tesaro.